Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

876 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.
Ptashkin RN, Ewalt MD, Jayakumaran G, Kiecka I, Bowman AS, Yao J, Casanova J, Lin YD, Petrova-Drus K, Mohanty AS, Bacares R, Benhamida J, Rana S, Razumova A, Vanderbilt C, Balakrishnan Rema A, Rijo I, Son-Garcia J, de Bruijn I, Zhu M, Lachhander S, Wang W, Haque MS, Seshan VE, Wang J, Liu Y, Nafa K, Borsu L, Zhang Y, Aypar U, Suehnholz SP, Chakravarty D, Park JH, Abdel-Wahab O, Mato AR, Xiao W, Roshal M, Yabe M, Batlevi CL, Giralt S, Salles G, Rampal R, Tallman M, Stein EM, Younes A, Levine RL, Perales MA, van den Brink MRM, Dogan A, Ladanyi M, Berger MF, Brannon AR, Benayed R, Zehir A, Arcila ME. Ptashkin RN, et al. Among authors: salles g. Nat Commun. 2023 Oct 28;14(1):6895. doi: 10.1038/s41467-023-42585-9. Nat Commun. 2023. PMID: 37898613 Free PMC article.
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
Stewart CM, Michaud L, Whiting K, Nakajima R, Nichols C, De Frank S, Hamlin PA Jr, Matasar MJ, Gerecitano JF, Drullinsky P, Hamilton A, Straus D, Horwitz SM, Kumar A, Moskowitz CH, Moskowitz A, Zelenetz AD, Rademaker J, Salles G, Seshan V, Schöder H, Younes A, Tsui DWY, Batlevi CL. Stewart CM, et al. Among authors: salles g. Clin Cancer Res. 2022 Jan 1;28(1):45-56. doi: 10.1158/1078-0432.CCR-21-2183. Epub 2021 Oct 6. Clin Cancer Res. 2022. PMID: 34615723 Free PMC article. Clinical Trial.
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
Shouval R, Alarcon Tomas A, Fein JA, Flynn JR, Markovits E, Mayer S, Olaide Afuye A, Alperovich A, Anagnostou T, Besser MJ, Batlevi CL, Dahi PB, Devlin SM, Fingrut WB, Giralt SA, Lin RJ, Markel G, Salles G, Sauter CS, Scordo M, Shah GL, Shah N, Scherz-Shouval R, van den Brink M, Perales MA, Palomba ML. Shouval R, et al. Among authors: salles g. J Clin Oncol. 2022 Feb 1;40(4):369-381. doi: 10.1200/JCO.21.02143. Epub 2021 Dec 3. J Clin Oncol. 2022. PMID: 34860572 Free PMC article.
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.
Sha F, Okwali M, Alperovich A, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Khan N, Kumar A, Matasar MJ, Moskowitz AJ, Noy A, Owens C, Palomba LM, Rodriguez-Rivera I, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Schöder H, Seshan VE, Salles G, Younes A, Batlevi CL. Sha F, et al. Among authors: salles g. Blood Cancer J. 2022 Feb 10;12(2):29. doi: 10.1038/s41408-022-00620-w. Blood Cancer J. 2022. PMID: 35145059 Free PMC article.
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
Qualls D, Lam HY, Whiting K, Kumar A, Matasar M, Owens C, Nichols C, Espeleta JA, Qiu A, Subzwari S, Biggar E, Seshan V, Salles G, Younes A, Batlevi C. Qualls D, et al. Among authors: salles g. Blood Adv. 2022 Sep 27;6(18):5262-5266. doi: 10.1182/bloodadvances.2021006555. Blood Adv. 2022. PMID: 35171976 Free PMC article. Clinical Trial. No abstract available.
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, Chung DJ, Doddi S, Falchi L, Gyurkocza B, Hamilton A, Lin YH, Jakubowski AA, Joffe E, Landau HL, Lin RJ, Mailankody S, Palomba ML, Park JH, Perales MA, Ponce DM, Ramanathan LV, Salles GA, Scordo M, Seo SK, Shah UA, Stein EM, Straus D, Usmani SZ, Young JW, Zelenetz AD, Noy A, Vardhana SA. Stuver R, et al. Cancer Cell. 2022 Jun 13;40(6):590-591. doi: 10.1016/j.ccell.2022.05.007. Epub 2022 May 16. Cancer Cell. 2022. PMID: 35598602 Free PMC article. No abstract available.
Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.
Morschhauser F, Salles G, Batlevi CL, Tilly H, Chaidos A, Phillips T, Burke J, Melnick A. Morschhauser F, et al. Among authors: salles g. Blood Rev. 2022 Nov;56:100988. doi: 10.1016/j.blre.2022.100988. Epub 2022 Jul 9. Blood Rev. 2022. PMID: 35851487 Free PMC article. Review.
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma.
Nath K, Tomas AA, Flynn J, Fein JA, Alperovich A, Anagnostou T, Batlevi CL, Dahi PB, Fingrut WB, Giralt SA, Lin RJ, Palomba ML, Peled JU, Salles G, Sauter CS, Scordo M, Fraint E, Feuer E, Shah N, Slingerland JB, Devlin S, Shah GL, Gupta G, Perales MA, Shouval R. Nath K, et al. Among authors: salles g. Transplant Cell Ther. 2022 Nov;28(11):751.e1-751.e7. doi: 10.1016/j.jtct.2022.08.001. Epub 2022 Aug 6. Transplant Cell Ther. 2022. PMID: 35944603 Free PMC article.
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
Qualls D, Noy A, Straus D, Matasar M, Moskowitz C, Seshan V, Dogan A, Salles G, Younes A, Zelenetz AD, Batlevi CL. Qualls D, et al. Among authors: salles g. Leuk Lymphoma. 2023 Mar;64(3):738-741. doi: 10.1080/10428194.2022.2164194. Epub 2023 Jan 15. Leuk Lymphoma. 2023. PMID: 36642966 Free PMC article. Clinical Trial. No abstract available.
876 results